GCM
TMO icon

Geneva Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Geneva Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
3,553
-593
-14% -$285K 0.04% 108
2026
Q1 		$2.04M Sell
4,146
-785
-16% -$426K 0.04% 109
2025
Q4 		$2.86M Sell
4,931
-51
-1% -$28.8K 0.05% 105
2025
Q3 		$2.42M Sell
4,982
-191
-4% -$88.9K 0.04% 110
2025
Q2 		$2.1M Buy
5,173
+636
+14% +$266K 0.04% 111
2025
Q1 		$2.26M Sell
4,537
-79
-2% -$42.8K 0.04% 109
2024
Q4 		$2.4M Sell
4,616
-332
-7% -$183K 0.04% 115
2024
Q3 		$3.06M Sell
4,948
-430
-8% -$255K 0.05% 111
2024
Q2 		$2.97M Sell
5,378
-1,341
-20% -$768K 0.05% 113
2024
Q1 		$3.91M Sell
6,719
-336
-5% -$189K 0.07% 106
2023
Q4 		$3.74M Sell
7,055
-354
-5% -$171K 0.07% 104
2023
Q3 		$3.75M Buy
7,409
+644
+10% +$343K 0.08% 106
2023
Q2 		$3.53M Sell
6,765
-287
-4% -$155K 0.07% 105
2023
Q1 		$4.06M Sell
7,052
-526
-7% -$296K 0.08% 102
2022
Q4 		$4.17M Sell
7,578
-822
-10% -$436K 0.09% 104
2022
Q3 		$4.26M Sell
8,400
-3
-0% -$1.68K 0.1% 106
2022
Q2 		$4.57M Sell
8,403
-93
-1% -$51.2K 0.11% 104
2022
Q1 		$5.02M Buy
8,496
+106
+1% +$60.9K 0.1% 111
2021
Q4 		$5.6M Sell
8,390
-201
-2% -$125K 0.09% 108
2021
Q3 		$4.91M Sell
8,591
-254
-3% -$139K 0.08% 112
2021
Q2 		$4.46M Sell
8,845
-36
-0.4% -$17K 0.07% 112
2021
Q1 		$4.05M Sell
8,881
-91
-1% -$43.4K 0.07% 114
2020
Q4 		$4.18M Buy
8,972
+12
+0.1% +$5.63K 0.07% 113
2020
Q3 		$3.96M Buy
8,960
+79
+0.9% +$32.6K 0.08% 107
2020
Q2 		$3.22M Buy
8,881
+79
+0.9% +$26.5K 0.07% 108
2020
Q1 		$2.5M Buy
+8,802
New +$2.78M 0.07% 110

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geneva Capital Management's TMO Position: Q2 2026 in Review

Geneva Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 14% in Q2 2026, selling an estimated $285K and leaving 3,553 shares worth $1.78M. The position accounts for 0.04% of the portfolio, ranked #108.

Geneva Capital Management first reported a position in TMO in Q1 2020 and has held it in 26 quarters since. The position peaked at $5.6M in Q4 2021. 2,617 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Geneva Capital Management held 3,553 shares of Thermo Fisher Scientific worth $1.78M as of Q2 2026.
  • Geneva Capital Management sold 593 Thermo Fisher Scientific shares in Q2 2026, an estimated $285K.
  • Thermo Fisher Scientific made up 0.04% of Geneva Capital Management's portfolio in Q2 2026, its #108 holding.
  • Geneva Capital Management first reported a position in Thermo Fisher Scientific in Q1 2020 and has held it in 26 quarters since.
  • Geneva Capital Management's Thermo Fisher Scientific position peaked at $5.6M in Q4 2021.
  • 2,617 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.